Carlos A. DiazGranados

Author

Also Known As

C. A. DiazGranados, C. Diazgranados, C.A. DiazGranados, Carlos A DiazGranados, Carlos A Diazgranados, Carlos A. DiazGranados, Carlos A. DiazGranados (8486010), Carlos A. Diazgranados, Carlos DiazGranados, Carlos Diazgranados

Publications

6.1K

Citations

H-Index

Concepts

All Affiliations

Sanofi (United States)Sanofi (France)Fred Hutch Cancer Center Emory University Walter Reed Army Institute of Research

About

Carlos A. DiazGranados is an author at Sanofi (United States) specializing in medicine, vaccination, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	1K
2	Epidemiology	9	9	489
3	Public Health	4	4	281
4	Health Sciences	2	2	179
5	Allergy	2	2	150

Carlos A. DiazGranados

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults Carlos A. DiazGranados, Andrew J. Dunning, Murray Kimmel, New England Journal of Medicine	2014	820
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy Saranya Sridhar, Alexander R. Luedtke, Edith Langevin, New England Journal of Medicine	2018	756
Transmission of West Nile Virus from an Organ Donor to Four Transplant Recipients Martha Iwamoto, Daniel B. Jernigan, Antonio Guasch, New England Journal of Medicine	2003	695
Prevention of <i>M. tuberculosis</i> Infection with H4:IC31 Vaccine or BCG Revaccination Elisa Nemes, Hennie Geldenhuys, Virginie Rozot, New England Journal of Medicine	2018	650
Impact of Vancomycin Resistance on Mortality among Patients with Neutropenia and Enterococcal Bloodstream Infection Carlos A. DiazGranados, John A. Jernigan The Journal of Infectious Diseases Bacterial ResistanceRetrospective Cohort StudyAntimicrobial SusceptibilityHealth SciencesAntibiotics	2005	159
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study Paul A. Goepfert, Bo Fu, Anne-Laure Chabanon, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccinologyVaccine DevelopmentImmunology	2021	123
High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: Safety, immunogenicity and relative efficacy during the 2009–2010 season Carlos A. DiazGranados, Andrew J. Dunning, Emilia Jordanov, Vaccine VaccinologyVaccine SafetyVaccinationPreventive MedicineElderly Adults	2012	122
Prospective audit for antimicrobial stewardship in intensive care: Impact on resistance and clinical outcomes Carlos A. DiazGranados American Journal of Infection Control AntibioticsAntimicrobial StewardshipMedicineHealthcare-associated InfectionPatient Safety	2011	122
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial Linda‐Gail Bekker, Zoe Moodie, Nicole Grunenberg, The Lancet HIV	2018	121
Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines Carlos A. DiazGranados, Corwin A. Robertson, H. Keipp Talbot, Vaccine	2015	112

Page 1